Patents by Inventor Brigitte Devaux

Brigitte Devaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-tumor antibody compositions and methods of use
    Patent number: 7435416
    Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: October 14, 2008
    Assignee: Genetech, Inc.
    Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence A. Lasky
  • Agonist anti-trk-C monoclonal antibodies
    Patent number: 7384632
    Abstract: The invention concerns agonist anti-trkC monoclonal antoibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: June 10, 2008
    Assignee: Genentech, Inc.
    Inventors: Brigitte Devaux, David L. Shelton, Jo-Anne Hongo, Leonard G. Presta
  • Methods of treating coagulapathic or thrombotic disorders
    Patent number: 7354585
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: April 8, 2008
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Brigitte Devaux, Dan L. Eaton, Philip E. Hass, J. Kevin Judice, Daniel Kirchhofer, Shelley Suggett
  • Agonist anti-trk-C monoclonal antibodies
    Publication number: 20070036794
    Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Application
    Filed: October 16, 2006
    Publication date: February 15, 2007
    Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard Presta, David Shelton
  • Human anti-factor IX/IXa antibodies
    Publication number: 20060193851
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Application
    Filed: March 31, 2006
    Publication date: August 31, 2006
    Inventors: Camellia Adams, Brigitte Devaux, Dan Eaton, Philip Hass, J. Judice, Daniel Kirchhofer, Shelley Suggett
  • Human anti-factor IX/IXa antibodies
    Patent number: 7049411
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: May 23, 2006
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Brigitte Devaux, Dan L. Eaton, Philip E. Hass, J. Kevin Judice, Daniel Kirchhofer, Shelley Suggett
  • HUMAN ANTI-FACTOR IX/IXA ANTIBODIES
    Publication number: 20060088534
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Application
    Filed: July 8, 2003
    Publication date: April 27, 2006
    Inventors: Camellia Adams, Brigitte Devaux, Dan Eaton, Philip Hass, J. Judice, Daniel Kirchhofer, Shelley Suggett
  • Anti-tumor antibody compositions and methods of use
    Publication number: 20050036942
    Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.
    Type: Application
    Filed: September 8, 2004
    Publication date: February 17, 2005
    Applicant: Genentech, Inc.
    Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence Lasky
  • Anti-tumor antibody compositions and methods of use
    Patent number: 6824780
    Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: November 30, 2004
    Assignee: Genentech, Inc.
    Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence A. Lasky
  • Agonist anti-trk-c monoclonal antibodies
    Publication number: 20040137513
    Abstract: The invention concerns agonist anti-trkC monoclonal antoibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Application
    Filed: October 30, 2003
    Publication date: July 15, 2004
    Inventors: Brigitte Devaux, David L. Shelton, Jo-Anne Hongo, Leonard G. Presta
  • PUMPCn compositions and uses thereof
    Publication number: 20040005598
    Abstract: The present invention is directed to novel polypeptides Protein Upregulated in Metastatic Prostate Cancer (PUMPCn) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: March 19, 2003
    Publication date: January 8, 2004
    Applicant: Genentech, Inc.
    Inventors: Brigitte DeVaux, David Eberhard, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Kenneth J. Hillan, Colin K. Watanabe, William I. Wood, Daniel Yansura, Zemin Zhang
  • Human anti-factor IX/IXa antibodies
    Patent number: 6624295
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of-FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: September 23, 2003
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Brigitte Devaux, Dan L. Eaton, Philip E. Hass, J. Kevin Judice, Daniel Kirchhofer, Shelley Suggett